oncology

Indications

Non-Hodgkin’s Lymphoma (NHL)

RIABNI^® (rituximab-arrx) is indicated for the treatment of adult patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.
Chronic Lymphocytic Leukemia (CLL)

RIABNI^®, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL.
Rheumatoid Arthritis (RA)
- RIABNI^®, in combination with methotrexate, is indicated for the treatment of adult patients with moderately- to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)
RIABNI^®, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA).

WHEN YOU CHOOSE RIABNI^®

AMGEN OFFERS PERSONALIZED SUPPORT FOR YOUR PATIENTS

Riabni^® is A rituximab biosimilar that provides the Amgen level of support to your patients and practice

RIABNI^® is FDA approved for all Rituxan^® oncology indications^1,2

*When diluted in 0.9% Sodium Chloride injection, USP

FDA = Food and Drug Administration.

Non-Hodgkin's lymphoma (NHL)
- - Follicular lymphoma (FL)
- - Previously untreated large B-cell lymphoma
- - Non-progressing (stable disease)
Previously untreated chronic lymphocytic leukemia (CLL)

*When diluted in 0.9% Sodium Chloride injection, USP

FDA = Food and Drug Administration.

IMPORTANT SAFETY INFORMATION AND INDICATIONS

BOXED WARNINGS: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

Warnings and Precautions

Tumor Lysis Syndrome

Infections

Cardiovascular Adverse Reactions

Renal Toxicity

Bowel Obstruction and Perforation

Immunization

Embryo-Fetal Toxicity

Concomitant Use with Other Biologic Agents and DMARDs other than Methotrexate in RA, GPA, and MPA

Use in RA Patients Who Have Not Had Prior Inadequate Response to Tumor Necrosis Factor (TNF) Antagonists

Most Common Adverse Reactions

Attention Healthcare Provider: Provide Medication Guide to patient prior to RIABNI^® infusion and advise patients to read guide.

INDICATIONS

IMPORTANT SAFETY INFORMATION AND INDICATIONS

BOXED WARNINGS: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

Warnings and Precautions

Infusion-Related reactions (IRR)

Severe Mucocutaneous Reactions

Hepatitis B Virus Reactivation

Progressive Multifocal Leukoencephalopathy (PML)

Tumor Lysis Syndrome

Infections

Cardiovascular Adverse Reactions

Renal Toxicity

Bowel Obstruction and Perforation

Immunization

Embryo-Fetal Toxicity

Additional Important Safety Information

Adverse Reactions

Pregnancy and Nursing Mothers

Attention Healthcare Provider: Provide Medication Guide to patient prior to RIABNI^® infusion and advise patients to read guide.

Indications

Non-Hodgkin’s Lymphoma (NHL)

Chronic Lymphocytic Leukemia (CLL)

RIABNI™ (rituximab-arrx) has anestablished Q-Code:

IMPORTANT SAFETY INFORMATION AND INDICATIONS

BOXED WARNINGS: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

Warnings and Precautions

Tumor Lysis Syndrome

Infections

Cardiovascular Adverse Reactions

Renal Toxicity

Bowel Obstruction and Perforation

Immunization

Embryo-Fetal Toxicity

Concomitant Use with Other Biologic Agents and DMARDs other than Methotrexate in RA, GPA, and MPA

Use in RA Patients Who Have Not Had Prior Inadequate Response to Tumor Necrosis Factor (TNF) Antagonists

Most Common Adverse Reactions

Attention Healthcare Provider: Provide Medication Guide to patient prior to RIABNI® infusion and advise patients to read guide.

INDICATIONS

IMPORTANT SAFETY INFORMATION AND INDICATIONS

BOXED WARNINGS: FATAL INFUSION-RELATED REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

Warnings and Precautions

Infusion-Related reactions (IRR)

Severe Mucocutaneous Reactions

Hepatitis B Virus Reactivation

Progressive Multifocal Leukoencephalopathy (PML)

Tumor Lysis Syndrome

Infections

Cardiovascular Adverse Reactions

Renal Toxicity

Bowel Obstruction and Perforation

Immunization

Embryo-Fetal Toxicity

Additional Important Safety Information

Adverse Reactions

Pregnancy and Nursing Mothers

Attention Healthcare Provider: Provide Medication Guide to patient prior to RIABNI® infusion and advise patients to read guide.

Indications

Non-Hodgkin’s Lymphoma (NHL)

Chronic Lymphocytic Leukemia (CLL)

Connect with an Amgen Oncology representative

Privacy Statement

RIABNI™
(rituximab-arrx) has an
established Q-Code:

Attention Healthcare Provider: Provide Medication Guide to patient prior to RIABNI^® infusion and advise patients to read guide.

Attention Healthcare Provider: Provide Medication Guide to patient prior to RIABNI^® infusion and advise patients to read guide.